IMNN files 8-K; Q2-25 earnings press release furnished, call set for Aug 5

Q: When will Imunon (IMNN) discuss its Q2 2025 results?

Management will host a live conference call and webcast on August 5, 2025 .

Q: Where can investors access the Imunon earnings webcast?

The webcast will stream at http://www.imunon.com .

Q: Does this 8-K include Imunon's Q2 2025 financial figures?

No. The numerical results are in Exhibit 99.1 , which is furnished separately.

Q: Is the information in this filing considered "filed" with the SEC?

No. It is furnished under Item 2.02 and not subject to Exchange Act 搂18 liability.

Q: Which SEC form number applies to this Imunon report?

This document is a Form 8-K current report.

[8-K] Imunon, Inc. Reports Material Event

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Form 8-K (Item 2.02) 鈥� Imunon, Inc. (NASDAQ: IMNN) is furnishing, not filing, its Q2-25 financial results press release and related conference-call details.

The company issued a press release on 5 Aug 2025 covering results for the quarter ended 30 Jun 2025; the full text is attached as Exhibit 99.1.
A live webcast and teleconference to review the quarter and provide a business update will be held the same day (5 Aug 2025) and can be accessed at www.imunon.com.
Under SEC rules, the furnished information is exempt from liability under Exchange Act 搂18 and will not be incorporated by reference into other SEC filings unless specifically stated.
No quantitative financial figures, guidance, or strategic actions are included in this 8-K; investors must refer to Exhibit 99.1 for actual performance metrics.

Other than the routine disclosure of results timing and webcast logistics, the filing contains no material new information or corporate actions.

Insights

TL;DR 鈥� Routine 8-K; only announces that Q2-25 earnings release and call are available.

This is a standard Item 2.02 furnishing. Because the underlying press release is not provided here, the 8-K itself offers no financial metrics, forward guidance, or strategic developments. Market impact should be driven by the actual numbers and commentary in Exhibit 99.1 and the webcast, not by this filing. From a compliance standpoint, management properly limits liability by furnishing rather than filing. Overall sentiment: neutral, with importance contingent on external earnings details.

08/05/2025 - 08:03 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

Imunon, Inc.

(Exact name of registrant as specified in its Charter)

Delaware

001-15911

52-1256615

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2025, Imunon, Inc. issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On July 29, 2025, Imunon, Inc. announced it would hold a conference call on August 5, 2025 to discuss its financial results for the quarter ended June 30, 2025 and provide a business update. The conference call will also be broadcast live on the internet at http://www.imunon.com.

The information in this report, including the exhibit hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Imunon, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

The press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

99.1		Press Release dated August 5, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON INC.

Dated: August 5, 2025	By:	/s/ Kimberly Graper
		Kimberly Graper
		Chief Financial Officer

Source:

FAQ

When will Imunon (IMNN) discuss its Q2 2025 results?

Management will host a live conference call and webcast on August 5, 2025.

Where can investors access the Imunon earnings webcast?

The webcast will stream at http://www.imunon.com.

Does this 8-K include Imunon's Q2 2025 financial figures?

No. The numerical results are in Exhibit 99.1, which is furnished separately.

Is the information in this filing considered "filed" with the SEC?

No. It is furnished under Item 2.02 and not subject to Exchange Act 搂18 liability.

Which SEC form number applies to this Imunon report?

This document is a Form 8-K current report.

AG真人官方

[8-K] Imunon, Inc. Reports Material Event

Insights

FAQ

When will Imunon (IMNN) discuss its Q2 2025 results?

Where can investors access the Imunon earnings webcast?

Does this 8-K include Imunon's Q2 2025 financial figures?

Is the information in this filing considered "filed" with the SEC?

Which SEC form number applies to this Imunon report?

NASDAQ:IMNN

IMNN Rankings

IMNN Latest News

IMNN Latest SEC Filings

IMNN Stock Data

AG真人官方

Trending News

[8-K] Imunon, Inc. Reports Material Event

Insights

Sell-side Equity Analyst neutral

FAQ

When will Imunon (IMNN) discuss its Q2 2025 results?

Where can investors access the Imunon earnings webcast?

Does this 8-K include Imunon's Q2 2025 financial figures?

Is the information in this filing considered "filed" with the SEC?

Which SEC form number applies to this Imunon report?

NASDAQ:IMNN

IMNN Rankings

IMNN Latest News

IMNN Latest SEC Filings

IMNN Stock Data